Wide Ranks

EBS

Emergent BioSolutions Inc.

10.11

Top Statistics
Market Cap 547 M Forward PE 3.38 Revenue Growth 8.60 %
Current Ratio 2.88 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -18.55 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -223.73 Enterprise / Revenue 0.9540 Price To Sales Trailing12 Months 0.4867
Profitability
Profit Margins -18.55 % Operating Margins 24.51 %
Balance Sheet
Total Cash 149 M Total Cash Per Share 2.77 Total Debt 676 M
Total Debt To Equity 132.97 Current Ratio 2.88 Book Value Per Share 9.40
All Measures
Short Ratio 442.00 % Message Board Id finmb_13627017 Fax 240 631 3203
Shares Short Prior Month 7 M Return On Equity -0.3464 City Gaithersburg
Uuid 248c1b0b-cb74-394b-ab4a-08030c4a6847 Previous Close 10.03 First Trade Date Epoch Utc 1 B
Book Value 9.40 Beta 1.57 Total Debt 676 M
Volume 755026 Price To Book 1.08 Fifty Two Week Low 1.42
Total Cash Per Share 2.77 Total Revenue 1 B Shares Short Previous Month Date 1 B
Target Median Price 12.00 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins 24.51 % Target Mean Price 12.00 Net Income To Common -208800000
Ask 10.15 Short Percent Of Float 0.1528 Implied Shares Outstanding 54 M
Last Fiscal Year End 1 B Trailing Peg Ratio None Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 149 M Next Fiscal Year End 1 B
Revenue Per Share 21.45 Held Percent Insiders 0.0209 Ebitda Margins -0.43 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 10.03 Target Low Price 12.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 8.96 Open 10.05 Free Cashflow 89 M
State MD Dividend Yield 0.00 % Return On Assets -0.0422
Time Zone Short Name EST Trailing Eps -3.91 Day Low 9.84
Address1 400 Professional Drive Shares Outstanding 54 M Price Hint 2
Target High Price 12.00 Website https://www.emergentbiosolutions.com 52 Week Change 3.72
Average Volume 1 M Forward Eps 2.99 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 118.00 % Is_sp_500 False
Regular Market Day High 10.33 Profit Margins -18.55 % Debt To Equity 132.97
Fifty Two Week High 15.10 Day High 10.33 Shares Short 6 M
Regular Market Open 10.05 Industry Key drug-manufacturers-specialty-generic Bid 9.94
Earnings Growth 0.00 % Enterprise To Revenue 0.9540 Revenue Growth 8.60 %
Shares Percent Shares Out 0.1257 Operating Cashflow 170 M Currency USD
Time Zone Full Name America/New_York Market Cap 547 M Is_nasdaq_100 False
Zip 20879 Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic
Long Name Emergent BioSolutions Inc. Regular Market Day Low 9.84 Held Percent Institutions 0.5991
Current Price 10.11 Address2 Suite 400 Enterprise To Ebitda -223.73
Financial Currency USD Current Ratio 2.88 Gross Margins 25.79 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 1 Country United States
Float Shares 53 M Two Hundred Day Average 6.63 Ir Website http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-irhome#node/150
Enterprise Value 1 B Price To Sales Trailing12 Months 0.4867 Forward PE 3.38
Regular Market Volume 755026 Ebitda -4800000 Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.

The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector.

In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections.

Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services.

The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.